In one of the recent decision by the US trade representative, Indian IP should be kept away from the US IPR priority list. This decision took place after the US industry had raised the matter of India's rejection of patents for Bristol-Myers Squibb's Sprycel and Novartis AG's Glivec. Intellectual Property Office, India has always maintained that its IPR regime is fully compliant with WTO norms and it would drag the US to the global trade body if any adverse unilateral step is taken against the country in IPR-related matters.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.